Triple-negative metastatic breast cancer
Metastatic triple-negative breast cancer is a rare form of aggressive breast cancer. Learn more its symptoms, diagnosis, and treatment options.
- Medical Review: Rita Nanda, MD
Metastatic breast cancer is breast cancer that has spread outside of the breast to other areas of the body, such as the bones, liver, lungs, or brain. Triple-negative breast cancer is a form of breast cancer that tests negative for estrogen receptor, progesterone receptor, and HER2 receptor expression, hence the nickname triple-negative. If you’re diagnosed with triple-negative breast cancer, it means that antiestrogen therapy or HER2-targeting medicines will not be helpful in treating the cancer. Still, there are a number of effective treatment options available.
Early-stage triple-negative breast cancer is more likely to spread to other areas of the body than other types of breast cancer. In fact, one study found that people with early TNBC were four times more likely to develop metastases. Other research suggests one-third of people with early TNBC will develop metastases. Doctors sometimes call TNBC an aggressive breast cancer because it is more likely to recur, often within the first 4 years after diagnosis.
Anyone can develop triple-negative breast cancer, but research shows certain groups have a higher likelihood of developing it, including:
If early-stage breast cancer recurs, the cancer cells’ receptor status can sometimes be different than they were at the time of the original diagnosis. If you are experiencing a recurrence of an early-stage breast cancer, your medical oncologist should recommend that you have a biopsy. The biopsy helps to:
- Diagnose the cancer
- Confirm the cancer is metastatic
- Confirm the receptor status
You can find more information on how metastatic breast cancer is diagnosed on our pages about metastatic breast cancer and testing.
Receiving a diagnosis of metastatic triple-negative metastatic breast cancer (mTNBC) can feel scary, and it can sometimes feel isolating. Triple-negative breast cancer accounts for approximately 15 percent of all breast cancers. Maybe you’ve heard people say that TNBC is hard to manage because it can’t be treated with hormonal therapies or HER2-targeting medicines like some other breast cancers can. In the past, this was true. But medical advances have introduced treatment options for mTNBC, and a number of new treatments are being studied specifically for mTNBC. You have more options than just chemotherapy. These treatments include:
- Immunotherapy (pembrolizumab)
- Targeted therapies, including PARP inhibitors and an antibody-drug conjugate (ADC) called sacituzumab govitecan (Trodelvy)
Understanding more about this diagnosis can bring a greater sense of control as you and your care team decide on the most effective treatments for you. Below, we’ll walk you through mTNBC in more detail, from diagnosis to treatment and living long term with the disease.
What are the symptoms of triple-negative metastatic breast cancer?
For some people, metastatic breast cancer is found before it causes symptoms, on an imaging scan done as a follow-up after early-stage breast cancer. Others experience symptoms that lead them to see their doctor. The symptoms of triple-negative metastatic breast cancer are the same symptoms seen in other types of metastatic breast cancer. These symptoms can vary depending on where in the body the cancer cells traveled. Below are a few symptoms associated with the four most common areas of breast cancer metastases: the bones, liver, lungs, and brain. For a fuller list of symptoms, visit our page on metastatic breast cancer symptoms.
Bone:
- Unexplained pain in one or more bones
- A fracture or break caused by normal activity
Liver:
- Sudden weight loss or loss of appetite
- Swelling or pain in the abdomen
- Swelling of the legs
Lungs:
- Shortness of breath doing normal activity
- Dry cough
- Coughing up blood
- Chest pain or pain with breathing
Brain:
- Frequent headaches
- Dizziness or balance problems
- Changes in speech, behavior, or vision
All areas of the body:
How triple-negative metastatic breast cancer is diagnosed
The tests used to diagnose metastatic triple-negative breast cancer are the same tests commonly used to diagnose any kind of metastatic breast cancer. Your doctor will likely recommend a biopsy of the new area of cancer to confirm whether it is triple-negative, hormone receptor-positive, or HER2 receptor-positive, because this information guides your treatment options. In addition to a confirming biopsy, you may need additional tests:
- Blood tests can provide information about whether cancer has traveled to organs such as the bones or liver. They can also check for blood tumor markers that may indicate metastasis and can look for signs of anemia that may be a side effect of chemotherapy.
- Bone scans can help doctors learn whether breast cancer has spread to the bones, and to monitor how bone metastases are responding to treatment.
- CAT scans, also called CT scans, create digital x-rays of the inside of organs so doctors can check for areas of possible cancer spread. They can also be used to determine whether treatment is shrinking a tumor.
- PET scans can detect areas of metastasis by capturing images of cancer cell activity throughout the body.
- MRI creates 3D images of the body to detect areas of metastasis and to monitor the cancer’s response to treatment.
You may also be offered genetic testing and genetic counseling. More than 75 percent of breast cancers diagnosed in people who carry a BRCA gene mutation are triple-negative. Even if you’ve already been diagnosed with mTNBC, knowing your BRCA mutation status can help in important ways:
- Getting a confirmation that you carry a BRCA mutation can help answer questions about why you may have developed cancer.
- If you test positive, you can inform family members about your status so they can have an opportunity to be tested if they choose to do so.
- Most importantly, metastatic breast cancers that develop in people who have a BRCA gene mutation can be treated with PARP inhibitors.
If you have genetic testing, it’s best to do so with the guidance of your physician or a genetic counselor who can help you understand your results. Learn more on our page about genetic counseling.
Recent medical advances have introduced new treatment options for mTNBC, and a number of new treatments are being studied specifically for mTNBC. You have more options than just chemotherapy.
In the past, triple-negative breast cancers of all stages, including mTNBC, could only be treated with chemotherapy. Now, there are more treatments available to treat mTNBC, including immunotherapy and targeted therapies such as PARP inhibitors and antibody-drug conjugates (ADCs):
- Immunotherapy stimulates the body’s immune system to attack cancer cells. Pembrolizumab (Keytruda) is the only immunotherapy currently approved for mTNBC.
- PARP inhibitors stop an enzyme called PARP from repairing cell DNA. There are two PARP inhibitors for mTNBC: olaparib (Lynparza) and talazoparib (Talzenna). To be eligible for these treatments, you must also carry a BRCA mutation.
- Antibody-drug conjugates deliver chemotherapy into cancer cells by targeting specific proteins on the cancer cells. Sacituzumab govitecan (Trodelvy) is the only ADC currently approved to treat mTNBC. However, a number of other ADCs that target mTNBC are showing promise, and may be approved in the future.
As the cancer grows and changes, chemotherapy may still be part of your treatment. There are many chemotherapy options available to treat mTNBC, and different chemotherapy drugs can cause different side effects. It’s important to talk with your care team about your goals in treating the cancer as well as your goals for daily life. The chemotherapy treatments available to you depends on your exact diagnosis and which cancer treatments you’ve had in the past, if any.
There are three types of chemotherapy most often used for metastatic triple-negative breast cancer:
- Anthracyclines kill cancer cells by stopping cell growth. The three anthracyclines used in metastatic breast cancer are:
- Liposomal doxorubicin HCl liposome injection (Doxil)
- Doxorubicin (Adriamycin) (sometimes, but not often, used to treat mTNBC)
- Epirubicin (Ellence) (sometimes, but not often, used to treat mTNBC)
- Taxanes slow or stop tumor growth by stopping cells from dividing. The three taxanes given for metastatic disease are:
- Platinum-based chemotherapies interfere with the action of DNA inside cancer cells. Some platinum-based medicines are:
- Cisplatin (Platinol)
- Carboplatin (Paraplatin)
Other types of chemotherapy may also be used:
- Capecitabine (Xeloda), given alone or with docetaxel or paclitaxel, is effective against some cancers that stop responding to anthracyclines or taxanes.
- Vinorelbine (Navelbine) prevents the function of microtubules, which help cancer cells divide. It can be used alone or with other chemotherapy medicines.
- Gemcitabine (Gemzar) works by starving cancer cells of the nutrition they need to grow. Gemcitabine is usually given with carboplatin. Gemcitabine, given with paclitaxel, is FDA approved for use when an anthracycline stops working or you can’t take it for other reasons.
- Ixabepilone (Ixempra) stops the growth of tumor cells by targeting a protein called tubulin that helps cells multiply. It is approved for use when other chemotherapy medicines don’t work against the cancer or when the cancer stops responding to treatment.
- Eribulin (Halaven) stops the cancer cells from dividing into new cells by interfering with the parts of the cell that help move the information inside them during cell division. It is approved for use in people whose metastatic breast cancer has grown after treatment with at least two other types of chemotherapy, including an anthracycline and a taxane.
Living with triple-negative metastatic breast cancer
Being diagnosed with mTNBC can be overwhelming. It can be hard to think about your daily needs and emotional health when you need to navigate the healthcare system, manage medical bills, and cope with treatment side effects. Be gentle with yourself. Living with metastatic breast cancer means being in treatment indefinitely, so even small steps toward better physical and mental health are extremely important.
The most important thing you can do to maintain the best quality of life possible is to see your medical oncologist regularly and inform them of how the treatment you are receiving is affecting you. When you start treatment, you and your care team will create a plan for treatments as well as any blood tests and scans needed to see how well treatments are working. If the cancer stops responding to one treatment, you may be offered a new one.
Making some lifestyle choices can also help you feel stronger and healthier during treatment. Eating a healthy diet and talking with your doctor about safely maintaining or starting an exercise routine can help with side effects and supporting a sense of well-being. Early research suggests that a doctor-approved exercise routine during metastatic breast cancer treatment can ease pain, fatigue, and anxiety.
Some people also find relief from stress and side effects by supporting their medical treatment with complementary therapies, practices that are not medical but that can be helpful physically and emotionally. Complementary therapies include:
- Acupuncture
- Art therapy
- Massage
- Reiki
- Yoga
- Music therapy
You can learn more about complementary therapies and how to access them by reading our page on complementary therapy.
Clinical trials
Triple-negative breast cancer is a huge field of study for cancer researchers right now. Clinical trials are underway to look at how TNBC responds to new and emerging treatments. Most of the time, treatment trials are open to people with metastatic disease before they open up to people with early-stage disease. This means if you’ve been diagnosed with mTNBC, you have a good chance of qualifying for a clinical trial that’s exploring a new medicine.
While the idea of joining a trial can bring feelings of uncertainty for some people, the reality is that trials offer more check-ins with your care team than standard treatment. Clinical trials can be a way to get access to an effective treatment before it becomes available to the general population. Clinical trials are not a last resort. You can join a clinical trial at any time during treatment for mTNBC as long as you meet the trial’s eligibility requirements.
Learn more about clinical trials.
We know that a diagnosis of metastatic triple-negative breast cancer can trigger intense feelings, and that making treatment decisions can be exhausting and overwhelming. Below you’ll find articles, personal stories, and downloadable resources to help you make sense of the basics of your diagnosis, from understanding the disease to coping with the lifestyle changes that come with it.
Related news
- Promising ctDNA study ends early due to low enrollment | SABCS 2024
- Addition of palbociclib improves outcomes in HER2-positive, hormone receptor-positive metastatic breast cancer | SABCS 2024
- Imlunestrant proves effective against hormone receptor-positive, HER2-negative advanced breast cancer | SABCS 2024
- A new era in dosing: Dose optimization | SABCS 2024
Free downloads
View allStay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.
- 3-dimensional radiation therapy
- 4-hydroxytamoxifen
- ablation
- abnormal
- Abraxane
- absolute risk
- AC regimen
- AC-T regimen
- AC-T-T regimen
- AC-Taxol regimen
- AC-TH regimen
- accelerated partial-breast irradiation
- action study
- acupoint
- acupressure
- acupuncture
- acupuncture needle
- acupuncture point
- acupuncture point injection
- acupuncturist
- acustimulation
- acute
- acute pain
- adenocarcinoma
- adenopathy
- adenosis
- adjunct agent
- adjunct therapy
- adjunctive therapy
- adjuvant therapy
- advance directive
- advanced practice nurse
- adverse effect
- aerobic exercise
- agent study
- aggravating factor
- aggressive
- AJCC staging system
- Alkeran
- alkylating agent
- Allegra
- allopathic medicine
- alopecia
- amifostine
- aminoglutethimide
- amitriptyline
- anabolic steroid
- analgesic
- anaplastic
- anastrozole
- ancillary test
- anemia
- anesthesia
- anesthesiologist
- angiogenesis
- angiogenesis inhibitor
- antagonist
- anthracycline
- anti-anxiety medicine
- anti-idiotype vaccine
- anti-inflammatory
- antibody-dependent cellular cytotoxicity
- antibody therapy
- anticachexia
- anticancer antibiotic
- anticancer therapy
- anticonvulsant
- antidepressant
- antiemetic
- antiestrogen
- antifolate
- antigen-presenting cell vaccine
- antihormone therapy
- antimetabolite
- antimitotic agent
- antineoplastic
- antitumor
- anxiety
- anxiolytic
- Anzemet
- APN
- apocrine gland
- apoptosis
- aprepitant
- areola
- Aromasin
- aromatase inhibitor
- aromatherapy
- arthralgia
- ascites
- aspirate
- aspiration
- assay
- asthenia
- asymptomatic
- atypia
- atypical ductal hyperplasia
- atypical hyperplasia
- atypical lobular hyperplasia
- avoidance
- axillary lymph node
- axillary lymph node dissection
- BAK gel
- balloon catheter radiation
- baseline
- behavior modification
- best practice
- BI-RADS
- Biafine cream
- bias
- bilateral
- bilateral breast cancer
- bilateral prophylactic mastectomy
- bilateral salpingo-oophorectomy
- biofeedback
- biologic
- biopsy
- biopsy specimen
- biotherapy
- bisphosphonate
- bisphosphonate-associated osteonecrosis
- blinded study
- blood-brain barrier
- blood-brain barrier disruption
- blood cell count
- blood chemistry study
- board certified oncology pharmacy specialist
- body image
- body mass index
- bolus dose
- bone density
- bone metastasis
- bone mineral density scan
- bone scan
- bone-seeking radioisotope
- brachytherapy
- brain metastasis
- BRCA1
- BRCA2
- BRCAPro
- breast carcinoma in situ
- breast-conserving surgery
- breast density
- breast duct
- breast duct endoscopy
- breast lobe
- breast lobule
- breast reconstruction
- breast self-exam
- Brief Pain Inventory
- cachexia
- CAF regimen
- calcification
- cancer vaccine
- candidiasis
- capecitabine
- carboplatin
- carcinogen
- carcinoma
- carcinoma in situ
- carcinomatous meningitis
- carcinosis
- carcinostatic
- cardiotoxicity
- caregiver
- carmustine
- case-control study
- case report
- case series
- CAT scan
- CBC
- cell
- cell-cycle regulation
- cell proliferation
- central nervous system
- central nervous system metastasis
- central nervous system prophylaxis
- central venous access catheter
- cetuximab
- cevimeline
- chaplain
- charged-particle radiation therapy
- chemoembolization
- chemoimmunotherapy
- chemoprevention
- chemoprevention study
- chemoprotective
- chemoradiation
- chemosensitivity
- chemosensitivity assay
- chemosensitizer
- chemotherapeutic agent
- chemotherapy
- chest wall
- chest X-ray
- Chinese meridian theory
- chronic
- chronic pain
- cisplatin
- Claus model
- clergy
- clinical
- clinical breast exam
- clinical practice guidelines
- clinical researcher
- clinical resistance
- clinical series
- clinical stage
- clinical staging
- clinical study
- clinical trial
- clinician
- clodronate
- CMF regimen
- cognition
- cognitive behavior therapy
- cognitive therapy
- cohort
- cohort study
- coinsurance
- combination chemotherapy
- comedo carcinoma
- comfort care
- Coming Out
- Community Advisory Board
- comorbidity
- compassionate use trial
- complementary and alternative medicine
- complementary medicine
- complete metastasectomy
- complete remission
- complete response
- complex decongestive therapy
- compliance
- complication
- compression garment
- computed tomography scan
- concomitant
- concurrent therapy
- condition
- consolidation therapy
- constitutional acupuncture
- continuum of care
- contract research organization
- contraindication
- contralateral
- contrast material
- control group
- controlled clinical trial
- controlled study
- conventional medicine
- conventional therapy
- copayments
- cope
- coping skills
- core biopsy
- core needle biopsy
- corticosteroid
- counseling
- COX inhibitor
- cryoablation
- cryopreservation
- cryosurgery
- CT scan
- cultural competency
- cumulative dose
- cumulative exposure
- cure
- cutaneous
- cutaneous breast cancer
- cyclophosphamide
- cyclosporine
- CYP2D6 inhibitor
- cystosarcoma phyllodes
- cytopenia
- cytotoxic
- cytotoxic chemotherapy
- Cytoxan
- Data and Safety Monitoring Board
- DCIS
- de novo
- debulking
- deductible
- definitive surgery
- definitive treatment
- dehydration
- denosumab
- depression
- diagnosis
- diagnostic mammogram
- diagnostic procedure
- diagnostic technique
- diagnostic trial
- diameter
- diarrhea
- diaziquone
- DIEP flap
- dietary counseling
- dietary supplement
- dietitian
- differentiation
- diffuse
- digital mammography
- diphenhydramine
- discharge
- disease progression
- disease-specific survival rate
- distant cancer
- distant metastasis
- Distant recurrence
- distress
- DNR order
- docetaxel
- dolasetron
- dose
- dose-dense chemotherapy
- dose-dependent
- dose-limiting
- dose-rate
- double-blinded
- doxorubicin
- drain
- dronabinol
- droperidol
- drug interaction
- drug resistance
- drug therapy
- drug tolerance
- duct
- ductal carcinoma
- ductal carcinoma in situ
- ductal lavage
- duloxetine
- durable power of attorney
- dysfunction
- dysgeusia
- dyspepsia
- dyspnea
- early menopause
- early-stage breast cancer
- edema
- EEG biofeedback
- efficacy
- Eklund displacement views
- electroacupuncture
- electron beam
- eligibility criteria
- Ellence
- emesis
- emetic
- endocrine
- endocrine therapy
- endpoint
- energy healing
- enteral nutrition
- epidemiology
- epirubicin
- ER+
- ER-
- ER
- ER-PR-HER2/neu-
- eribulin mesylate
- erythema
- estradiol
- estrogen
- estrogen blocker
- estrogen receptor
- estrogen receptor-negative
- estrogen receptor-positive
- estrogen receptor test
- estrogen replacement therapy
- etanidazole
- etidronate
- everolimus
- Evista
- excision
- excisional biopsy
- exemestane
- expanded access trial
- experimental
- extranodal
- false-negative test result
- false-positive test result
- familial cancer
- family medical history
- Faslodex
- fast-neutron beam radiation
- fatigue
- FDA
- febrile neutropenia
- FEC regimen
- Femara
- fertility
- fexofenadine
- fibroadenoma
- fibrocystic breast changes
- fiducial marker
- film mammography
- fine-needle aspiration biopsy
- first-degree relative
- first-line therapy
- five-year survival rate
- fluorouracil
- fluoxetine
- FNA biopsy
- focal
- Food and Drug Administration
- Fosamax
- fractionation
- fulvestrant
- functional magnetic resonance imaging
- gadolinium
- Gail model
- gallium scan
- gamma irradiation
- Gamma Knife therapy
- gamma ray
- Gelclair
- gemcitabine
- gene
- gene expression profile
- gene therapy
- general anesthesia
- generalized anxiety disorder
- generic
- genetic
- genetic counseling
- genetic marker
- genetic marker of susceptibility
- genetic predisposition
- genetic profile
- genetic susceptibility
- genetic testing
- genetic testing
- genetics
- genome
- genome-wide association study
- genomic profile
- genomic test
- genomics
- gland
- Good Clinical Practice
- goserelin
- grade
- grading
- granisetron
- gross description
- Halaven
- hazard ratio
- healing touch
- Health Insurance Portability and Accountability Act
- healthcare provider
- healthcare proxy
- healthy control
- helical computed tomography
- HER2/neu
- Herceptin
- hereditary
- hereditary mutation
- heteronormative
- high-dose chemotherapy
- high-dose radiation
- high-energy proton therapy
- high grade
- high-risk cancer
- HIPPA
- histologic examination
- histology
- historic cohort study
- historical control subject
- homeopathic medicine
- hormonal therapy
- hormone
- hormone receptor
- hormone receptor test
- hormone replacement therapy
- hormone responsive
- hormone therapy
- hospice
- hot flash
- human epidermal growth factor receptor 2
- human participant protection regulations
- hydroxydaunorubicin
- hyperalimentation
- hypercalcemia
- hyperfractionated radiation therapy
- hyperfractionation
- hyperplasia
- hypersensitivity
- hypofractionated radiation therapy
- hypofractionation
- hypoxia
- ibandronate
- ibuprofen
- idiopathic
- image-guided radiation therapy
- imaging
- imaging procedure
- immune adjuvant
- immune function
- immune response
- immune system
- immune system tolerance
- immunization
- immunoassay
- immunocompromised
- immunodeficiency
- immunohistochemistry
- immunology
- immunomodulation
- immunosuppression
- immunotherapy
- implant
- implant displacement views
- implant radiation therapy
- implantable pump
- in network
- in situ
- incidence
- incision
- incisional biopsy
- indication
- indolent
- induction therapy
- infection
- infertile
- infertility
- infiltrating breast cancer
- infiltrating ductal carcinoma
- inflammation
- inflammatory breast cancer
- informed consent
- infusion
- ingestion
- inherited
- iniparib
- injection
- inoperable
- insomnia
- Institutional Review Board
- intensification therapy
- intensity-modulated radiation therapy
- interfering thought
- internal mammary lymph nodes
- internal radiation therapy
- International Unit
- internist
- interstitial radiation therapy
- intervention
- intervention group
- intra-arterial
- intracarotid infusion
- intradermal
- intraductal breast papilloma
- intraductal carcinoma
- intrahepatic
- intrahepatic infusion
- intramuscular
- intramuscular injection
- intraoperative radiation therapy
- intraoperative ultrasound
- intratumoral
- intravasation
- intravenous
- intravenous infusion
- intravenous injection
- intrusive thought
- intrusive thoughts
- invasive breast cancer
- invasive cancer
- invasive procedure
- investigational
- investigator
- ionizing radiation
- ipsilateral
- IRB
- irradiated
- irradiation
- irreversible toxicity
- ixabepilone
- joint pain
- Karnofsky Performance Status
- laboratory test
- lapatinib
- laser
- laser surgery
- laser therapy
- lassitude
- late effects
- late-stage cancer
- latent
- laxative
- LEEP
- legal aid organization
- lesion
- lethargy
- letrozole
- leukopenia
- levels of evidence
- Lexapro
- libido
- lidocaine
- ligation
- linac
- linear accelerator
- lipoma
- lisofylline
- liver metastasis
- liver scan
- living will
- lobaplatin
- lobe
- lobectomy
- lobular carcinoma
- lobular carcinoma in situ
- lobule
- local anesthesia
- local cancer
- local therapy
- localization
- localized
- locally advanced cancer
- locally recurrent cancer
- lomustine
- loop electrosurgical excision procedure
- loop excision
- lorazepam
- low grade
- lubricant
- lumbar puncture
- lumpectomy
- lung metastasis
- luteinizing hormone-releasing hormone agonist
- lymph
- lymph gland
- lymph node
- lymph node dissection
- lymph node drainage
- lymph node mapping
- lymph vessel
- lymphadenectomy
- lymphadenopathy
- lymphangiogram
- lymphangiography
- lymphatic basin
- lymphatic fluid
- lymphatic mapping
- lymphatic system
- lymphatic vessel
- lymphedema
- lymphography
- lymphoscintigraphy
- Lyrica
- lytic lesion
- macrocalcification
- magnetic resonance imaging
- magnetic resonance perfusion imaging
- magnetic resonance spectroscopic imaging
- mainstream medicine
- maintenance therapy
- male breast cancer
- malignancy
- malignant
- malignant pleural effusion
- malnutrition
- mammary
- mammary dysplasia
- mammary gland
- mammogram
- mammography
- MammoSite
- Mammotome
- mantle field
- MAO inhibitor
- margin
- marker
- mass
- massage therapy
- mastectomy
- mastitis
- maternal
- maximum tolerated dose
- mean survival time
- measurable disease
- medial supraclavicular lymph node
- median
- median survival time
- Medicaid
- medical castration
- medical device
- medical nutrition therapy
- medical oncologist
- Medicare
- medicine
- medullary breast carcinoma
- mega-voltage linear accelerator
- megestrol
- melphalan
- meningeal metastasis
- menopause
- menorrhagia
- menstrual cycle
- menstrual period
- menstruation
- mental health
- mental health counselor
- meridian
- mesna
- meta-analysis
- metallic
- metastasectomy
- metastasis
- metastasize
- metastatic
- methotrexate
- metoclopramide
- metronomic therapy
- microcalcification
- micrometastasis
- microscopic
- milk duct
- mind/body exercise
- mindfulness relaxation
- Miraluma test
- mitigate
- modified radical mastectomy
- molecular marker
- molecular medicine
- molecular risk assessment
- molecularly targeted therapy
- monoamine oxidase inhibitor
- monoclonal antibody
- morbidity
- mortality
- MRI
- MRSI
- MTD
- mTOR
- mucositis
- multicenter study
- multicentric breast cancer
- multidisciplinary
- multidisciplinary opinion
- multidrug resistance
- multidrug resistance inhibition
- multifocal breast cancer
- music therapy
- mutation
- mutation carrier
- myalgia
- myelosuppression
- nanoparticle paclitaxel
- narcotic
- National Cancer Institute
- National Center for Complementary and Alternative Medicine
- National Institutes of Health
- natural history study
- naturopathy
- nausea
- NCCAM
- NCI
- NCI clinical trials cooperative group
- needle biopsy
- needle localization
- needle-localized biopsy
- negative axillary lymph node
- negative test result
- neoadjuvant therapy
- neoplasm
- nerve
- nerve block
- neurocognitive
- neurologic
- neuropathy
- neurotoxicity
- neurotoxin
- neutropenia
- NIH
- nipple
- nipple discharge
- nitrosourea
- NMRI
- node-negative
- node-positive
- nodule
- nonblinded
- nonconsecutive case series
- noninvasive
- nonmalignant
- nonmetastatic
- nonprescription
- nonrandomized clinical trial
- nonsteroidal anti-inflammatory drug
- nonsteroidal aromatase inhibitor
- nontoxic
- normal range
- normative
- NP
- NPO
- NSAID
- nuclear grade
- nuclear magnetic resonance imaging
- nuclear medicine scan
- nurse
- nurse practitioner
- nutrition
- nutrition therapy
- nutritional counseling
- nutritional status
- nutritional supplement
- nutritionist
- obese
- objective improvement
- objective response
- observation
- observational study
- obstruction
- off-label
- olaparib
- oncologist
- oncology
- oncology nurse
- oncology pharmacy specialist
- oncolysis
- ondansetron
- onset of action
- oophorectomy
- open biopsy
- open label study
- open resection
- operable
- opiate
- opioid
- opportunistic infection
- oral
- organ
- orthodox medicine
- osteolytic
- osteonecrosis of the jaw
- osteopenia
- osteoporosis
- OTC
- out of network
- outcome
- outpatient
- ovarian
- ovarian ablation
- ovarian cancer
- ovarian suppression
- ovary
- over-the-counter
- overall survival rate
- overdose
- overexpress
- overweight
- ovulation
- PA
- paclitaxel
- paclitaxel albumin-stabilized nanoparticle formulation
- paclitaxel-loaded polymeric micelle
- Paget disease of the nipple
- pain threshold
- palliation
- palliative care
- palliative therapy
- palmar-plantar erythrodysesthesia
- palonosetron hydrochloride
- palpable disease
- palpation
- palpitation
- pamidronate
- panic
- papillary tumor
- Paraplatin
- parenteral nutrition
- paroxetine hydrochloride
- PARP
- PARP inhibitor
- partial-breast irradiation
- partial mastectomy
- partial oophorectomy
- partial remission or partial response
- pastoral counselor
- paternal
- pathologic fracture
- pathological stage
- pathological staging
- pathologist
- pathology report
- patient advocate
- Paxil
- peau d'orange
- pedigree
- peer-review process
- peer-reviewed scientific journal
- perfusion magnetic resonance imaging
- perimenopausal
- periodic neutropenia
- perioperative
- peripheral neuropathy
- peripheral venous catheter
- personal health record
- personal medical history
- personalized medicine
- Pertuzumab
- PET scan
- pharmacist
- phase I/II trial
- phase I trial
- phase II/III trial
- phase II trial
- phase III trial
- phase IV trial
- phlebotomy
- photon beam radiation therapy
- phyllodes tumor
- physical examination
- physical therapist
- physical therapy
- physician
- physician assistant
- physiologic
- PI3 kinase inhibitor
- pilocarpine
- pilot study
- placebo
- placebo-controlled
- plastic surgeon
- plastic surgery
- population study
- positive axillary lymph node
- positive test result
- positron emission tomography scan
- post-traumatic stress disorder
- postmenopausal
- postoperative
- postremission therapy
- potentiation
- power of attorney
- PR
- PR+
- PR-
- practitioner
- preauthorization
- precancerous
- preclinical study
- predictive factor
- pregabalin
- premalignant
- premature menopause
- premenopausal
- premium
- prescription
- prevention
- preventive
- preventive mastectomy
- primary care
- primary care doctor
- primary endpoint
- primary therapy
- primary treatment
- primary tumor
- Principal investigator
- prochlorperazine
- progesterone
- progesterone receptor
- progesterone receptor-negative
- progesterone receptor-positive
- progesterone receptor test
- progestin
- prognosis
- prognostic factor
- progression
- progression-free survival
- progressive disease
- Prolia
- proliferative index
- promegapoietin
- prophylactic
- prophylactic mastectomy
- prophylactic oophorectomy
- prophylactic surgery
- prophylaxis
- prospective
- prospective cohort study
- prosthesis
- protective factor
- protein
- protein-bound paclitaxel
- protein expression
- protein expression profile
- protocol
- proton
- proton magnetic resonance spectroscopic imaging
- pruritus
- psychiatrist
- psychological
- psychologist
- psychosocial
- psychotherapy
- PTSD
- pump
- punch biopsy
- qi
- qigong
- quadrantectomy
- quality assurance
- quality of life
- radiation
- radiation brachytherapy
- radiation dermatitis
- radiation fibrosis
- radiation necrosis
- radiation nurse
- radiation oncologist
- radiation physicist
- radiation surgery
- radiation therapist
- radiation therapy
- radical lymph node dissection
- radical mastectomy
- radioactive
- radioactive drug
- radioactive seed
- radioisotope
- radiologic exam
- radiologist
- radiology
- radionuclide
- radionuclide scanning
- radiopharmaceutical
- radiosensitization
- radiosensitizer
- radiosurgery
- radiotherapy
- raloxifene
- raloxifene hydrochloride
- randomization
- randomized clinical trial
- receptor
- RECIST
- reconstructive surgeon
- reconstructive surgery
- recreational therapy
- recurrence
- recurrent cancer
- referral
- reflexology
- refractory
- refractory cancer
- regimen
- regional
- regional anesthesia
- regional cancer
- regional chemotherapy
- regional lymph node
- regional lymph node dissection
- registered dietician
- regression
- rehabilitation
- rehabilitation specialist
- relapse
- relative survival rate
- relaxation technique
- remission
- remission induction therapy
- remote brachytherapy
- research nurse
- research study
- resectable
- resected
- resection
- residual disease
- resistant cancer
- resorption
- respite care
- response rate
- retrospective cohort study
- retrospective study
- risk factor
- Rubex
- salpingo-oophorectomy
- salvage therapy
- samarium 153
- sargramostim
- scalpel
- scan
- scanner
- scintigraphy
- scintimammography
- sclerosing adenosis
- screening
- screening mammogram
- second-line therapy
- second-look surgery
- second primary cancer
- secondary cancer
- secrete
- sedative
- segmental mastectomy
- selection bias
- selective estrogen receptor modulator
- selective serotonin reuptake inhibitor
- sentinel lymph node
- sentinel lymph node biopsy
- sentinel lymph node mapping
- sepsis
- sequential AC/Taxol-Trastuzumab regimen
- sequential treatment
- SERM
- sertraline
- Serzone
- sestamibi breast imaging
- sexuality
- sibling
- side effect
- silicone
- simple mastectomy
- simulation
- Single-agent therapy
- sleep disorder
- social service
- social support
- social worker
- sodium thiosulfate
- soft tissue
- solid tumor
- somatic
- somatic mutation
- sorafenib
- specialist
- specificity
- spiculated mass
- spinal anesthesia
- spinal block
- spiral CT scan
- spirituality
- sporadic cancer
- SSRI
- stable disease
- stage
- stage 0 breast carcinoma in situ
- stage 0 disease
- stage I breast cancer
- stage IA breast cancer
- stage IB breast cancer
- stage II breast cancer
- stage II breast cancer
- stage IIA breast cancer
- stage IIB breast cancer
- stage III breast cancer
- stage III lymphedema
- stage IIIA breast cancer
- stage IIIB breast cancer
- stage IIIC breast cancer
- stage IV breast cancer
- staging
- stamina
- standard of care
- standard therapy
- statistically significant
- stent
- stereotactic biopsy
- stereotactic radiosurgery
- sterile
- sternum
- steroid
- stress
- strontium
- study agent
- subcutaneous
- subcutaneous port
- subjective improvement
- subset analysis
- supplemental nutrition
- supplementation
- support group
- supportive care
- supraclavicular lymph node
- surgeon
- surgery
- surgical biopsy
- surgical menopause
- surgical oncologist
- survival rate
- symptom
- symptom management
- symptomatic
- synergistic
- synthetic
- syringe
- systemic
- systemic chemotherapy
- systemic disease
- systemic therapy
- TAC regimen
- tai chi
- tailored intervention
- talk therapy
- tamoxifen
- targeted therapy
- taxane
- Taxol
- Taxotere
- Tc 99m sulfur colloid
- technician
- terminal disease
- therapeutic
- therapeutic touch
- therapy
- thermography
- thiethylperazine
- thiotepa
- third-line therapy
- thrush
- time to progression
- tinnitus
- tissue
- tissue flap reconstruction
- TNM staging system
- tomography
- tomotherapy
- topical
- topical chemotherapy
- topoisomerase inhibitor
- total estrogen blockade
- total mastectomy
- total nodal irradiation
- total parenteral nutrition
- toxic
- toxicity
- tracer
- traditional acupuncture
- tranquilizer
- transdermal
- transfusion
- transitional care
- translational research
- trastuzumab
- trauma
- treatment field
- trigger
- trigger point acupuncture
- triple-negative breast cancer
- tumescent mastectomy
- tumor
- tumor antigen vaccine
- tumor board review
- tumor burden
- tumor debulking
- tumor load
- tumor marker
- tumor volume
- Tykerb
- ulcer
- ulceration
- ultrasound-guided biopsy
- ultrasound/ultrasonography
- ultraviolet radiation therapy
- uncontrolled study
- undifferentiated
- unilateral
- unilateral salpingo-oophorectomy
- unresectable
- unresected
- upstaging
- urticaria
- VACB
- vaccine therapy
- vacuum-assisted biopsy or vacuum-assisted core biopsy
- Valium
- vancomycin
- vandetanib
- vascular endothelial growth factor-antisense oligonucleotide
- vascular endothelial growth factor receptor tyrosine kinase inhibitor
- vein
- Velban
- venipuncture
- venous sampling
- Versed
- vertebroplasty
- vinorelbine
- vital
- vomit
- watchful waiting
- wedge resection
- Wellcovorin
- Western medicine
- WGA study
- white blood cell
- whole cell vaccine
- whole genome association study
- wide local excision
- wire localization
- wound
- X-ray therapy
- Xanax
- Xeloda
- xerostomia
- Xgeva
- yoga
- ziconotide
- Zinecard
- Zofran
- zoledronic acid
- Zoloft
- Zometa
Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical, and evidence-based content. For over 30 years, the organization has remained committed to creating a culture of acceptance — where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, learn more about our programs and services.